Get the Stockscreener App
1.105
5.98%
-0.065
FibroGen Inc stock is currently priced at $1.105, with a 24-hour trading volume of 938.73K.
It has seen a -5.98% decreased in the last 24 hours and a -53.19% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.20 pivot point. If it approaches the $1.05 support level, significant changes may occur.
FibroGen Inc Stock (FGEN) Financials Data
FibroGen Inc (FGEN) Revenue 2024
FGEN reported a revenue (TTM) of $147.75 million for the quarter ending December 31, 2023, a +4.99% rise year-over-year.
FibroGen Inc (FGEN) Net Income 2024
FGEN net income (TTM) was -$284.23 million for the quarter ending December 31, 2023, a +3.21% increase year-over-year.
FibroGen Inc (FGEN) Cash Flow 2024
FGEN recorded a free cash flow (TTM) of -$317.54 million for the quarter ending December 31, 2023, a -71.95% decrease year-over-year.
FibroGen Inc (FGEN) Earnings per Share 2024
FGEN earnings per share (TTM) was -$2.93 for the quarter ending December 31, 2023, a +6.69% growth year-over-year.
FibroGen Inc Stock (FGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Henderson Jeffrey William | Director |
Sep 01 '23 |
Sale |
1.03 |
2,000 |
2,060 |
28,866 |
| Henderson Jeffrey William | Director |
Aug 04 '23 |
Sale |
1.91 |
2,000 |
3,820 |
30,866 |
| Henderson Jeffrey William | Director |
Jul 11 '23 |
Sale |
2.69 |
2,000 |
5,380 |
32,866 |
| Conterno Enrique A | Chief Executive Officer |
Jul 07 '23 |
Sale |
2.80 |
1,880 |
5,264 |
374,722 |
| Wettig Thane | Chief Commercial Officer |
Jun 23 '23 |
Sale |
16.53 |
791 |
13,075 |
108,261 |
| Chung Christine | SVP, China Operations |
Jun 14 '23 |
Sale |
16.79 |
6,250 |
104,925 |
236,327 |
| Chung Christine | SVP, China Operations |
Jun 13 '23 |
Sale |
17.60 |
6,250 |
110,000 |
242,577 |
| Blaug Suzanne | Director |
Jun 09 '23 |
Sale |
17.20 |
8,520 |
146,571 |
29,594 |
| EDWARDS JEFFREY L | Director |
Jun 09 '23 |
Sale |
17.19 |
7,889 |
135,622 |
33,977 |
| Brennan Aoife | Director |
Jun 09 '23 |
Sale |
17.19 |
4,733 |
81,367 |
27,947 |
FibroGen Inc Stock (FGEN) Latest News
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Zacks Investment Research
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Zacks Investment Research
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
Zacks Investment Research
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
Zacks Investment Research
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Zacks Investment Research
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Zacks Investment Research
About FibroGen Inc
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
COMPANY PROFILE
NameFibroGen Inc
SectorHealthcare (1194)
IndustryBiotechnology (685)
Webfibrogen.com
Phone415-978-1200
Employee423
Twitter
@FibroGenInc
SEC filings
Latest SEC Filings
Next earning date2024-05-06
Address409 Illinois Street, San Francisco, CA, United States (94158)
1.63%
1.08%
Cap:
|
Volume (24h):